CAMBRIDGE, Mass. and BEIJING, China, April 29, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its BTK inhibitor BRUKINSA™ (zanubrutinib) and its anti-PD-1 antibody tislelizumab will be presented in an oral presentation and three posters at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place on May 29-31, 2020.
Oral Presentation:
| Title: | ASPEN: Results of a Phase III Randomized Trial of Zanubrutinib Versus Ibrutinib for Patients with Waldenström Macroglobulinemia (WM) |
| Abstract #: | 8007 |
| Session Title: | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
| Lead Author: | Constantine S. Tam, MBBS, M.D., St. Vincent’s Hospital, Australia |
Poster Presentations:
| Title: | Three-Year Follow-up of Treatment-Naïve and Previously Treated Patients with Waldenström Macroglobulinemia (WM) Receiving Single-Agent Zanubrutinib |
| Abstract #: | 8051 |
| Poster #: | 384 |
| Session Title: | Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia |
| Lead Author: | Constantine S. Tam, MBBS, M.D., St. Vincent’s Hospital, Australia |
| Title: | Phase 3 Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First line (1L) Treatment for Advanced Squamous Non-Small Cell Lung Cancer (sq NSCLC) |
| Abstract #: | 9554 |
| Poster #: | 320 |
| Session Title: | Lung Cancer—Non-Small Cell Metastatic Poster Session |
| Lead Author: | Jie Wang, M.D., Cancer Hospital Chinese Academy of Medical Sciences, China |
| Title: | Association Between Immune and Tumor Gene Signatures with Response or Resistance to Tislelizumab Monotherapy or in Combination with Chemotherapy in Gastroesophageal Adenocarcinoma |
| Abstract #: | 3115 |
| Poster #: | 179 |
| Session Title: | Developmental Therapeutics—Immunotherapy Poster Session |
| Lead Author | Jianming Xu, M.D., General Hospital of Chinese People’s Liberation Army, China |
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,500+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
| BeiGene Investor Contact | BeiGene Media Contact |
| Craig West +1 857-302-5189 ir@beigene.com | Liza Heapes +1 857-302-5663 media@beigene.com |